ClinicalTrials.gg
CompletedNCT01043874MACS0911Updated Apr 8, 2016Results posted

Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response

A Phase 4 interventional study of Nilotinib in Philadelphia Chromosome Positive and Chronic Myelogenous Leukemia in Chronic Phase, sponsored by Novartis Pharmaceuticals. Completed at 20 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-04-08.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 2 open to participants now, 3 under way, none of them phase 3. nilotinib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

Enrollment
37th of 66
45 · median 55
Started
2009
with 7 others
Phase 4
12 of 66
1 open now
Registered
18th of 66
by date
Lead sponsor
35 of 66
Novartis Pharmaceuticals

Among the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 37th largest by enrollment, is one of 8 that started in 2009, is one of 12 in phase 4, and was the 18th registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

2 of the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About nilotinib

nilotinib: first FDA approval 2007 (TASIGNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, or all of them as a file.
02

Study summary

To evaluate the major molecular response (MMR) rate at 12 months of nilotinib treatment on study in patients with Philadelphia Chromosome Positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP) who have a suboptimal molecular response to imatinib at 18 months or later.

03

Conditions studied

  • Philadelphia Chromosome Positive
  • Chronic Myelogenous Leukemia in Chronic Phase

Keywords

  • Chronic phase
  • Chronic myelogenous leukemia
  • CML
  • Philadelphia chromosome positive
  • Ph+
  • Nilotinib
  • CML-CP
  • Suboptimal molecular response
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients ≥ 18 years of age.
  2. 0, 1, or 2.
  3. Have been diagnosed with Ph+ CML-CP and receiving imatinib therapy.
  4. Patients with suboptimal molecular response to imatinib treatment continued for at least 18 months ( therapy)

    Suboptimal molecular response defined as all of the following conditions:

    1. Patients who have achieved CCyR (0% Ph+ chromosomes).
    2. Patients who don't achieve MMR (MMR defined as BCR-ABL/ABL ratio of ≤ 0.1% on the International Scale as detected by RQ-PCR).

    The treatment with imatinib defined as:

    Dose of 300 mg or higher daily must be maintained for a minimum of 3 months prior to study entry.

  5. Patients who meet the following laboratory tests criteria:

    1. total \< 1.5 x ,
    2. and SGPT \< 2.5 x ULN,
    3. creatinine \< 1.5 x ULN,
    4. Serum amylase and lipase ≤ 1.5 x ULN,
    5. Alkaline phosphatase ≤ 2.5 x ULN unless considered tumor related.
    6. Serum potassium, phosphorus, magnesium and calcium ≥ LLN or correctable with supplements prior to the first dose of study drug.
  6. Written prior to any study related screening procedures being performed.

Exclusion criteria

Exclusion Criteria:

  1. Prior accelerated phase or blast crisis CML.
  2. Previously documented T315I mutations.
  3. Presence of chromosomal abnormalities other than Ph+.
  4. Previous treatment with any other tyrosine kinase inhibitor except imatinib.
  5. Impaired cardiac function including any one of the following:

    1. Complete left bundle branch block
    2. Congenital long syndrome or family history of long QT syndrome
    3. History of or presence of significant ventricular or atrial tachyarrhythmias
    4. resting brachycardia (\<50 bpm)
    5. QTcF > 450 msec on screening
    6. Use of a ventricular-paced pacemaker
    7. Myocardial infarction during the last 12 months
    8. Other clinically significant heart disease (e.g. congestive heart failure, uncontrolled hypertension, unstable angina).
  6. Treatment with strong inducers (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, St John's Wort), and the treatment cannot be discontinued or switched to a different medication prior to starting study drug. See Section 6.4.3 for complete list of these medications.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Nilotinib

    400 mg BID

    Drug: Nilotinib

Interventions

06

What researchers measure

Primary outcomes

  1. MMR Rate at 12 Mos. of Nilotinib Treatment on Study in Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Who Have a Suboptimal Molecular Response to Imatinib at 18 Months or Later.

    MMR is defined as BCR-ABL ratio (%) on IS ≤ 0.1% (corresponds to ≥ 3 log reduction of BCR-ABL transcripts from standardized baseline value

    Time frame: 12 months after treatment

Secondary outcomes

  1. MMR Rate at 24 Months of Nilotinib Treatment on Study in Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

    MMR is defined as BCR-ABL ratio (%) on IS ≤ 0.1% (corresponds to ≥ 3 log reduction of BCR-ABL transcripts from standardized baseline value

    Time frame: 24 months after treatment

  2. Time to First MMR of Nilotinib in Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) .

    MMR is defined as BCR-ABL ratio (%) on IS ≤ 0.1% (corresponds to ≥ 3 log reduction of BCR-ABL transcripts from standardized baseline value

    Time frame: month 24

  3. Duration of MMR of Nilotinib in Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) .

    MMR is defined as BCR-ABL ratio (%) on IS ≤ 0.1% (corresponds to ≥ 3 log reduction of BCR-ABL transcripts from standardized baseline value

    Time frame: month 24

07

Results

Posted Feb 9, 2015

Participant flow

Participant flow — Overall Study
MilestoneNilotinib
Started45
Completed39
Not completed6
Withdrew: Adverse event3
Withdrew: Withdrawal by subject1
Withdrew: Lack of efficacy1
Withdrew: Administrative problems1

Outcome measures

PrimaryMMR Rate at 12 Mos. of Nilotinib Treatment on Study in Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Who Have a Suboptimal Molecular Response to Imatinib at 18 Months or Later.

MMR is defined as BCR-ABL ratio (%) on IS ≤ 0.1% (corresponds to ≥ 3 log reduction of BCR-ABL transcripts from standardized baseline value

Time frame:
12 months after treatment
Reported as:
Number · % participants achieving MMR
MMR Rate at 12 Mos. of Nilotinib Treatment on Study in Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Who Have a Suboptimal Molecular Response to Imatinib at 18 Months or Later.
% participants achieving MMRNilotinib
MMR Rate at 12 Mos. of Nilotinib Treatment on Study in Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Who Have a Suboptimal Molecular Response to Imatinib at 18 Months or Later.51.1 (35.8 to 66.3)
SecondaryMMR Rate at 24 Months of Nilotinib Treatment on Study in Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

MMR is defined as BCR-ABL ratio (%) on IS ≤ 0.1% (corresponds to ≥ 3 log reduction of BCR-ABL transcripts from standardized baseline value

Time frame:
24 months after treatment
Reported as:
Number · % participants achieving MMR
MMR Rate at 24 Months of Nilotinib Treatment on Study in Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
% participants achieving MMRNilotinib
MMR Rate at 24 Months of Nilotinib Treatment on Study in Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)66.7 (51.0 to 80.0)
SecondaryTime to First MMR of Nilotinib in Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) .

MMR is defined as BCR-ABL ratio (%) on IS ≤ 0.1% (corresponds to ≥ 3 log reduction of BCR-ABL transcripts from standardized baseline value

Time frame:
month 24
Reported as:
Mean · months
Time to First MMR of Nilotinib in Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) .
monthsNilotinib
Time to First MMR of Nilotinib in Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) .5.19 ± 5.494
SecondaryDuration of MMR of Nilotinib in Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) .

MMR is defined as BCR-ABL ratio (%) on IS ≤ 0.1% (corresponds to ≥ 3 log reduction of BCR-ABL transcripts from standardized baseline value

Time frame:
month 24
Reported as:
Number · % participants w/ durable MMR at 24 mos
Duration of MMR of Nilotinib in Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) .
% participants w/ durable MMR at 24 mosNilotinib
Duration of MMR of Nilotinib in Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) .51.1 (35.8 to 66.3)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nilotinib—7/45 (15.6%)45/45 (100%)
Most frequent serious events
Most frequent serious events
EventNilotinib
AnaemiaBlood and lymphatic system disorders1/45
Bile duct stoneHepatobiliary disorders1/45
PneumoniaInfections and infestations1/45
DehydrationMetabolism and nutrition disorders1/45
Chronic myeloid leukaemia transformationNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/45
Malignant neoplasm of renal pelvisNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/45
Erythema multiformeSkin and subcutaneous tissue disorders1/45
Most frequent other events
Showing 10 of 41
Most frequent other events
EventNilotinib
HyperbilirubinaemiaHepatobiliary disorders24/45
NasopharyngitisInfections and infestations21/45
HeadacheNervous system disorders17/45
RashSkin and subcutaneous tissue disorders15/45
Alanine aminotransferase increasedInvestigations14/45
HypophosphataemiaMetabolism and nutrition disorders13/45
Lipase increasedInvestigations11/45
ConstipationGastrointestinal disorders10/45
NauseaGastrointestinal disorders9/45
MyalgiaMusculoskeletal and connective tissue disorders9/45

Baseline characteristics

Age, Continuous
Age, Continuous(years)Nilotinib
Mean49.5 ± 14.89
Sex: Female, Male
Sex: Female, Male(Participants)Nilotinib
Female16
Male29
08

Study locations

20 sites
  • Novartis Investigative Site
    Nagoya-city, Aichi 453-8511, Japan
  • Novartis Investigative Site
    Nagoya-city, Aichi 466-8560, Japan
  • Novartis Investigative Site
    Nagoya, Aichi 464-8681, Japan
  • Novartis Investigative Site
    Fukuoka-city, Fukuoka 812-8582, Japan
  • Novartis Investigative Site
    Kitakyushu, Fukuoka 807-8556, Japan
  • Novartis Investigative Site
    Hiroshima-city, Hiroshima 734-8551, Japan
  • Novartis Investigative Site
    Kumamoto City, Kumamoto 860-8556, Japan
  • Novartis Investigative Site
    Sendai-city, Miyagi 983-8520, Japan
  • Novartis Investigative Site
    Nagasaki-city, Nagasaki 852-8501, Japan
  • Novartis Investigative Site
    Okayama-city, Okayama 700-8558, Japan
  • Novartis Investigative Site
    Osaka-city, Osaka 545-8586, Japan
  • Novartis Investigative Site
    OsakaSayama, Osaka 589-8511, Japan
  • Novartis Investigative Site
    Suita-city, Osaka 565-0871, Japan
  • Novartis Investigative Site
    Bunkyo-ku, Tokyo 113-8519, Japan
  • Novartis Investigative Site
    Bunkyo-ku, Tokyo 113-8655, Japan
  • Novartis Investigative Site
    Shinjuku-ku, Tokyo 160-0023, Japan
  • Novartis Investigative Site
    Aomori, 030-8553, Japan
  • Novartis Investigative Site
    Gifu, 501-1194, Japan
  • Novartis Investigative Site
    Kyoto, 602-8566, Japan
  • Novartis Investigative Site
    Saga, 849-8501, Japan
09

References and documents

Publications

  • Miyamura K, Miyamoto T, Tanimoto M, Yamamoto K, Kimura S, Kawaguchi T, Matsumura I, Hata T, Tsurumi H, Saito S, Hino M, Tadokoro S, Meguro K, Hyodo H, Yamamoto M, Kubo K, Tsukada J, Kondo M, Aoki M, Okada H, Yanada M, Ohyashiki K, Taniwaki M. Switching to nilotinib in patients with chronic myeloid leukemia in chronic phase with molecular suboptimal response to frontline imatinib: SENSOR final results and BIM polymorphism substudy. Leuk Res. 2016 Dec;51:11-18. doi: 10.1016/j.leukres.2016.09.009. Epub 2016 Sep 5. PubMed 27771544 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2009, a primary completion of Dec 2013 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2015, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2010
First posted
Jan 7, 2010
Start
Dec 2009
Primary completionActual
Dec 2013
CompletionActual
Jan 2014
Results first posted
Feb 9, 2015
Last update
Apr 8, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01043874
Responsible party
Sponsor
First posted
Jan 7, 2010
Start date
Dec 2009
Primary completion
Dec 2013
Completion
Jan 2014
Results posted
Feb 9, 2015
Last update
Apr 8, 2016

Study contacts

Novartis Pharma K.K.
study director · Novartis Pharma K.K.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nilotinib

Start the discussion